Related references
Note: Only part of the references are listed.Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial
Philip D. Home et al.
LANCET (2009)
Use of thiazolidinediones and fracture risk
Christian Meier et al.
ARCHIVES OF INTERNAL MEDICINE (2008)
Thiazolidinediones and cardiovascular outcomes in older patients with diabetes
Lorraine L. Lipscombe et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2007)
Effects of thiazolidinediones on bone loss and fracture
Catherine E. Murphy et al.
ANNALS OF PHARMACOTHERAPY (2007)
Thiazolidinediones and heart failure - A teleo-analysis
Sonal Singh et al.
DIABETES CARE (2007)
Rosiglitazone evaluated for cardiovascular outcomes - An interim analysis
Philip D. Home et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes
Steven E. Nissen et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy
Steven E. Kahn et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
Tutorial in biostatistics: The self-controlled case series method
Heather J. Whitaker et al.
STATISTICS IN MEDICINE (2006)
Inhaled corticosteroids and hip fracture - A population-based case-control study
RB Hubbard et al.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2002)
Epidemiology of fractures in England and Wales
TP Van Staa et al.
BONE (2001)
Use of statins and risk of fractures
TP van Staa et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2001)